<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ijerph-17-00440-t004" orientation="portrait" position="float">
 <object-id pub-id-type="pii">ijerph-17-00440-t004_Table 4</object-id>
 <label>Table 4</label>
 <caption>
  <p>Cost effectiveness.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Discounted Costs (in €), SVR12 Rates and ICER (€/SVR12 Percentage Point)</th>
   </tr>
   <tr>
    <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1"> </th>
    <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">Costs (in €)</th>
    <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">SVR12 Percentage Point</th>
    <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">ICER (€/SVR12 Percentage Point)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Triple Therapies</bold>
    </td>
    <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">171.017</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.85 *</td>
    <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">–</td>
   </tr>
   <tr>
    <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>DAA Therapies</bold>
    </td>
    <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">206.184</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.75 **</td>
    <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">€766.19/SVR12 Percentage Point</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>* Mean of SVR12 rates boceprevir + pegylated interferon + ribavirin non-cirrhotic + cirrhotic [
    <xref rid="B14-ijerph-17-00440" ref-type="bibr">14</xref>]; ** Mean of SVR12 rates sofosbuvir + ledipasvir ± ribavirin non-cirrhotic + cirrhotic [
    <xref rid="B14-ijerph-17-00440" ref-type="bibr">14</xref>]; ICER—incremental cost-effectiveness ratio.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
